The Department of Justice and DEA's April 23, 2026, final order rescheduled FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, delivering Section 280E tax relief and prompting registration applications from operators like Verano. This partial advancement, building on HHS's prior scientific recommendation, reflects administrative momentum but leaves broader recreational rescheduling unresolved. An expedited DEA administrative hearing starts June 29, 2026, to evaluate full marijuana transfer, amid emerging legal challenges and compliance hurdles like cGMP standards and FDA oversight. Traders assess this progress against hearing outcomes and potential litigation risks.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado$758,300 Vol.
31 mar 2026
30 de junio
3%
31 de diciembre
25%
$758,300 Vol.
30 de junio
$336,927 Vol.
3%
31 de diciembre
$156,491 Vol.
25%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Department of Justice and DEA's April 23, 2026, final order rescheduled FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, delivering Section 280E tax relief and prompting registration applications from operators like Verano. This partial advancement, building on HHS's prior scientific recommendation, reflects administrative momentum but leaves broader recreational rescheduling unresolved. An expedited DEA administrative hearing starts June 29, 2026, to evaluate full marijuana transfer, amid emerging legal challenges and compliance hurdles like cGMP standards and FDA oversight. Traders assess this progress against hearing outcomes and potential litigation risks.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado abierto: Feb 7, 2026, 5:04 PM ET
Volumen
$758,300Fecha de finalización
31 mar 2026Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Department of Justice and DEA's April 23, 2026, final order rescheduled FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, delivering Section 280E tax relief and prompting registration applications from operators like Verano. This partial advancement, building on HHS's prior scientific recommendation, reflects administrative momentum but leaves broader recreational rescheduling unresolved. An expedited DEA administrative hearing starts June 29, 2026, to evaluate full marijuana transfer, amid emerging legal challenges and compliance hurdles like cGMP standards and FDA oversight. Traders assess this progress against hearing outcomes and potential litigation risks.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$758,300Fecha de finalización
31 mar 2026Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The Department of Justice and DEA's April 23, 2026, final order rescheduled FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, delivering Section 280E tax relief and prompting registration applications from operators like Verano. This partial advancement, building on HHS's prior scientific recommendation, reflects administrative momentum but leaves broader recreational rescheduling unresolved. An expedited DEA administrative hearing starts June 29, 2026, to evaluate full marijuana transfer, amid emerging legal challenges and compliance hurdles like cGMP standards and FDA oversight. Traders assess this progress against hearing outcomes and potential litigation risks.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes